Immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia is now FDA approved – NCI Center for Cancer Research

NCI Center for Cancer Research shared a post on LinkedIn:

“BREAKTHROUGH IN TREATMENT: In 2012, Senior Investigator Ira Pastan, M.D., tested the immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia (HCL).

As a result, the drug is now an FDA approved therapy for the disease if it has recurred or progressed after at least two prior systemic therapies.

Read more.”

Source: NCI Center for Cancer Research/LinkedIn